Sermorelin
Sermorelin Research Peptide
Sermorelin is a synthetic peptide analogue corresponding to the biologically active N-terminal 29-amino acid fragment of endogenous human growth hormone releasing hormone (GHRH 1-29 NH2). This truncated sequence retains full GHRH receptor binding capacity and biological activity despite representing less than two-thirds of the complete native GHRH molecule, making Sermorelin a well-characterized and widely employed research tool for examining hypothalamic-pituitary somatotropic axis signaling, GHRH receptor pharmacology, and growth hormone secretion dynamics in controlled preclinical laboratory environments.
Sermorelin — Mechanism of Action
Sermorelin engages the GHRH receptor (GHRHR), a class B G-protein coupled receptor expressed predominantly on anterior pituitary somatotroph cells, with secondary expression documented across hypothalamic and peripheral tissue preparations in preclinical models. Receptor binding activates adenylyl cyclase through Gs-protein coupling, elevating intracellular cAMP concentrations and initiating downstream PKA signaling cascades that drive growth hormone gene transcription, biosynthesis, and pulsatile secretory release from pituitary granule stores. A particularly valuable characteristic of Sermorelin's preclinical pharmacological profile is its preservation of endogenous feedback regulation — by acting through the native GHRH receptor pathway rather than direct pituitary stimulation, Sermorelin-induced GH release remains subject to physiological somatostatin inhibition and IGF-1 negative feedback mechanisms, enabling investigation of intact hypothalamic-pituitary axis regulatory dynamics in experimental model systems.
Sermorelin — Research Background
Thorner et al. (1990) conducted seminal characterization of GHRH 1-29 fragment activity and receptor engagement properties, establishing the mechanistic foundation for Sermorelin's subsequent adoption as a standard preclinical somatotropic research tool. Preclinical pharmacology literature has consistently documented dose-dependent and reproducible GH secretion responses following Sermorelin administration in animal model systems, with published data supporting the preservation of physiological GH pulse architecture across repeated dosing protocols. Research by Vittone et al. examined Sermorelin's effects on somatotropic axis function across aging animal models, documenting its capacity to restore attenuated GH secretion patterns in aged subjects toward profiles more consistent with younger control populations. Additional preclinical investigation has explored Sermorelin activity in body composition research models, sleep architecture studies examining GH secretion during slow-wave sleep phases, and comparative secretagogue research designs evaluating GHRH receptor pathway dynamics relative to GHSR-mediated secretagogue mechanisms including Ipamorelin and GHRP-class peptides.
Sermorelin — Product Specifications & Storage
Form: Lyophilized powder
Purity: ≥98%, verified by analytical HPLC
Identity Confirmation: Mass spectrometry
Reconstitution: Sterile bacteriostatic water or normal saline recommended; allow equilibration to room temperature prior to use
Storage: −20°C optimal; protected from light and moisture
Post-Reconstitution Stability: 48–72 hours at 4°C; repeated freeze-thaw cycles should be avoided to preserve peptide structural integrity and biological activity
Research Use Only
Sermorelin is designated exclusively for preclinical and in vitro laboratory research applications. It is not approved for human use, therapeutic administration, or clinical investigation outside of regulated institutional oversight. All research protocols must conform to applicable institutional guidelines, animal care regulations, and biosafety procedures governing the handling of synthetic GHRH analogue research compounds.
